The HCV life cycle: In vitro tissue culture systems and therapeutic targets

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 525-537

  Gerold, Gisa ^a   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Cyclophilin A; Hepatitis C; Host targeting antivirals; MicroRNA 122; Phosphatidylinositol 4 kinase III

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; CYCLOPHILIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; GLYCOPROTEIN E2; INTERFERON; LOCKED NUCLEIC ACID; MICRORNA 122; MIRAVIRSEN; PHOSPHATIDYLINOSITOL 4 KINASE IIIALPHA; PHOSPHATIDYLINOSITOL KINASE; RIBAVIRIN; SCY 635; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; HOST FACTOR;

ARTICLE; CELL CULTURE; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIFE CYCLE; LIVER CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TISSUE CULTURE; TREATMENT OUTCOME; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; CULTURE TECHNIQUE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; ANTIVIRAL THERAPY; CONFERENCE PAPER; GENE TARGETING; INFECTION RISK; RNA REPLICATION; VIROLOGY;

ANIMALS; CELL CULTURE TECHNIQUES; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; TISSUE CULTURE TECHNIQUES; VIRUS REPLICATION;

EID: 84904677342     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360830     Document Type: Article

References (119)

1. Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107.
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002; 36:S35.
3. Brown RS: Hepatitis C and liver transplantation. Nature 2005; 436: 973.
4. Choo QL, et al: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359.
5. Simmonds P: The origin of hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 1.
6. Gottwein JM, et al: Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364.
7. Hayes CN, Imamura M, Aikata H, Chayama K: Genetics of IL28B and HCV - response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 406.
8. Prokunina-Olsson L, et al: A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164.
9. Doehring A, et al: Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther 2010; 15: 1099.
10. Lange CM, et al: Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2010; 55: 322-327.
11. Thomas DL, et al: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798.
12. Ge D, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399.
13. Wu X, et al: Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8:e1002617.
14. Schwartz RE, et al: Modeling hepatitis C virus infection using human-induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109: 2544.
15. Roelandt P, et al: Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012; 57: 246.
16. Buhler S, Bartenschlager R: New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32(suppl 1):9.
17. Scheel TK, Rice CM: Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837.
18. Manns MP, von Hahn T: Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013; 12: 595.
19. Lohmann V, et al: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110.
20. Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633.
21. Hsu M, et al: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271.
22. Wakita T, et al: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791.
23. Lindenbach BD, et al: Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623.
24. Zhong J, et al: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294.
25. Yi M, Lemon SM: Genotype 1a HCV (H77S) infection system. Methods Mol Biol 2009; 510: 337.
26. Li YP, et al: Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci USA 2012; 109: 19757.
27. Ramirez S, et al: Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology 2014; 59: 395-407.
28. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T: Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol 2008; 82: 7034.
29. Friebe P, Boudet J, Simorre JP, Bartenschlager R: Kissing-loop interaction in the 3 ? end of the hepatitis C virus genome essential for RNA replication. J Virol 2005; 79: 380.
30. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM: Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181.
31. Vieyres G, Pietschmann T: Entry and replication of recombinant hepatitis C viruses in cell culture. Methods 2013; 59: 233.
32. Lindenbach BD, et al: Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805.
33. Catanese MT, et al: Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 2013; 87: 8282.
34. Ploss A, et al: Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci USA 2010; 107: 3141-3145.
35. Marukian S, et al: Hepatitis C virus induces interferon-? and interferon-stimulated genes in primary liver cultures. Hepatology 2011; 54: 1913-1923.
36. Scarselli E, et al: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017.
37. Pileri P, et al: Binding of hepatitis C virus to CD81. Science 1998; 282: 938.
38. Evans MJ, et al: Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801.
39. Ploss A, et al: Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882.
40. Liu S, et al: Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009; 83: 2011.
41. Zeisel MB, et al: Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007; 46: 1722.
42. Koutsoudakis G, et al: Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308.
43. Sourisseau M, et al: Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog 2013; 9:e1003244.
44. Brazzoli M, et al: CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008; 82: 8316.
45. Farquhar MJ, et al: Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol 2012; 86: 4305.
46. Dorner M, et al: A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474: 208.
47. Meuleman P, et al: Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48: 1761.
48. Meuleman P, et al: A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55: 364.
49. Lacek K, et al: Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012; 57: 17.
50. Barth H, et al: Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006; 80: 10579.
51. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766.
52. Owen DM, Huang H, Ye J, Gale M Jr: Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99.
53. Lupberger J, et al: EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589.
54. Sainz B Jr, et al: Identification of the Niemann- Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281.
55. Martin DN, Uprichard SL: Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013; 110: 10777.
56. Gosert R, et al: Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487.
57. Egger D, et al: Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974.
58. Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R: Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol 2013; 87: 10612-10627.
59. Romero-Brey I, et al: Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 2012; 8:e1003056.
60. Quinkert D, Bartenschlager R, Lohmann V: Quantitative analysis of the hepatitis C virus replication complex. J Virol 2005; 79: 13594.
61. Herker E, et al: Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase- 1. Nat Med 2010; 16: 1295.
62. Menzel N, et al: MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog 2012; 8:e1002829.
63. Syder AJ, et al: Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54: 48.
64. Zhu H, et al: Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis 2012; 205: 656.
65. Sulkowski MS, et al: Safety and antiviral activity of the HCV entry inhibitor ITX 5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1B study. J Infect Dis 2014; 209: 658-667.
66. Chapel C, et al: Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol 2007; 88: 1133.
67. Chapel C, et al: Antiviral effect of ?-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J Gen Virol 2006; 87: 861.
68. Steinmann E, et al: Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330.
69. Durantel D: Celgosivir, an ?-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 2009; 10: 860.
70. Zhao G, et al: Validation of diacylglycerol acyltransferase 1 as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380.
71. Chatterji U, et al: The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009; 284: 16998.
72. Liu Z, Yang F, Robotham JM, Tang H: Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 2009; 83: 6554.
73. Kaul A, et al: Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009; 5: e1000546.
74. Yang F, et al: Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008; 82: 5269.
75. Watashi K, et al: Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111.
76. Foster TL, Gallay P, Stonehouse NJ, Harris M: Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J Virol 2011; 85: 7460.
77. Verdegem D, et al: Domain 3 of NS5A protein from the hepatitis C virus has intrinsic ?-helical propensity and is a substrate of cyclophilin A. J Biol Chem 2011; 286: 20441.
78. Chatterji U, et al: HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol 2010; 53: 50.
79. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282.
80. Lin K, Gallay P: Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res 2013; 99: 68.
81. Flisiak R, et al: The cyclophilin inhibitor Debio 025 combined with PEG IFN?2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460.
82. Nag A, Robotham JM, Tang H: Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol 2012; 86: 12616.
83. Pawlotsky J-M, et al: Alisporivir plus ribavirin is highly effective as interferon-free or interferon- add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b Study. J Hepatol 2012; 56:S553.
84. Von Hahn T, et al: Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. Gastroenterology 2012; 143: 439.
85. Hopkins S, et al: The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 2012; 57: 47.
86. Bobardt M, et al: HCV NS5A and IRF9 compete for CypA binding. J Hepatol 2013; 58: 16.
87. Watashi K, Daito T, Sluder A, Borroto-Esoda K, Wakita T: Cyclophilin inhibitors potentiate interferon signaling through diminished PKR phosphorylation in HCV-infected cells. J Hepatol 2013; 58:S5.
88. Supekova L, et al: Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008; 283: 29.
89. Tai AW, et al: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009; 5: 298.
90. Vaillancourt FH, et al: Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 2009; 387: 5.
91. Berger KL, et al: Roles for endocytic trafficking and phosphatidylinositol 4-kinase III? in hepatitis C virus replication. Proc Natl Acad Sci USA 2009; 106: 7577.
92. Borawski J, et al: Class III phosphatidylinositol 4-kinase ? and ? are novel host factor regulators of hepatitis C virus replication. J Virol 2009; 83: 10058.
93. Trotard M, et al: Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J 2009; 23: 3780.
94. Reiss S, et al: Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011; 9: 32.
95. Li Q, et al: A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA 2009; 106: 16410.
96. Ng TI, et al: Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007; 45: 1413.
97. Reiss S, et al: The lipid kinase phosphatidylinositol-4 kinase III? regulates the phosphorylation status of hepatitis C virus NS5A. PLoS pathogens 2013; 9:e1003359.
98. Vaillancourt FH, et al: Evaluation of phosphatidylinositol- 4-kinase III? as a hepatitis C virus drug target. J Virol 2012; 86: 11595.
99. Bianco A, et al: Metabolism of phosphatidylinositol 4-kinase III?-dependent PI4P is subverted by HCV and is targeted by a 4-anilino- quinazoline with antiviral activity. PLoS Pathog 2012; 8:e1002576.
100. Wilson RC, Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys 2013; 42: 217.
101. Grundhoff A, Sullivan CS: Virus-encoded microRNAs. Virology 2011; 411: 325.
102. Jopling CL, Schutz S, Sarnow P: Positiondependent function for a tandem micro- RNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008; 4: 77.
103. Henke JI, et al: microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300.
104. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM: Competing and noncompeting activities of miR-122 and the 5 ? -exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci USA 2013; 110: 1881.
105. Machlin ES, Sarnow P, Sagan SM: Masking the 5 ? -terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA- target RNA complex. Proc Natl Acad Sci USA 2011; 108: 3193.
106. Shimakami T, et al: Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA 2012; 109: 941.
107. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarno P: Modulation of hepatitis C virus RNA abundance by a liver-specific micro- RNA. Science 2005; 309: 1577.
108. Zhang C, et al: Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. Virology 2012; 433: 479.
109. Da Costa D, et al: Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol 2012; 86: 11919.
110. Vogt A, et al: Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology 2013; 444: 1-11.
111. Lanford RE, et al: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198.
112. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J: MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5 ? -UTR. Proc Natl Acad Sci USA 2011; 108: 4991.
113. Patick AK, et al: Sequence analysis of HCV variants from a phase IIA trial of miravirsen (MIR), an oligonucleotide targeting miR- 122, in treatment-naive patients with chronic HCV infection. J Hepatol 2012; 56:S476.
114. Reesink HW, et al: Final results - randomized, double-blind, placebo-controlled safety, anti-viral proof-of-concept study of miravirsen, an oligonucleotide targeting miR- 122, in treatment-naive patients with genotype 1 chronic HCV infection. J Hepatol 2012; 56:S26.
115. Persson R, et al: Pharmacokinetics of miravirsen, a miR-122 inhibitor, predict the prolonged viral load reduction in treatment-naive genotype 1 HCV-infected patients. J Hepatol 2012; 56:S477.
116. Hsu SH, et al: Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871.
117. De Chassey B, Meyniel-Schicklin L, Aublin- Gex A, Andre P, Lotteau V: New horizons for antiviral drug discovery from virus-host protein interaction networks. Curr Opin Virol 2012; 2: 606.
118. Kong L, et al: Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013; 342:1090-1094.
119. Khan AG, et al: Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014. DOI: 10.1038/nature13117. Epub ahead of print.